Glaukos price target raised to $105 from $90 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos to $105 from $90 and keeps an Overweight rating on the shares following a talk with a glaucoma clinician that believes Glaukos’ iDose is a “game changer in the space.” Piper sees a “modest ramp,” but continues to believe iDose will be a “massive product” for the company in the coming years